Roche lung cancer combo doubles PFS rates
admin 8th December 2017 Uncategorised 037 percent of patients had PFS for a year with Tecentriq and Avastin plus chemotherapy
More: Roche lung cancer combo doubles PFS rates
Source: News
37 percent of patients had PFS for a year with Tecentriq and Avastin plus chemotherapy
More: Roche lung cancer combo doubles PFS rates
Source: News
© 1994 - 2022 B.M. Pharmaceuticals